Summary of Significant Accounting Policies - Additional Information (Details)		3 Months Ended			6 Months Ended		12 Months Ended
	Mar. 25, 2022 USD ($) Market	Jun. 30, 2024 USD ($) Institution	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Jun. 30, 2024 USD ($) ReportingUnits Market Segment Institution	Jun. 30, 2023 USD ($)	Dec. 31, 2024	Dec. 31, 2023 USD ($)
Segment and Geographic Information
Number of operating segments | Segment					1
Cash Equivalents
Cash Equivalents		$ 315,700,000			$ 315,700,000
Concentration of Credit Risk
Number of financial institutions that hold the Company's cash | Institution		2			2
Business Combination
Intangible assets, Estimated period of benefit		8 years			8 years			9 years
Number of reporting units | ReportingUnits					1
Goodwill Remain Unchanged		$ 12,042,000			$ 12,042,000			$ 12,042,000
Accounts Receivable, net
Accounts receivable, Allowance for credit loss		$ 0			$ 0
Equipment, net
Estimated useful life		3 years			3 years
Cost of Product Sales
Payment terms					60 days or less
Advertising costs		$ 30,300,000	$ 26,700,000		$ 54,300,000	$ 48,100,000
Income Taxes
Effective tax rate		0.00%	(0.90%)		0.00%	2.60%
Income tax expense		$ 0	$ (617,000)		$ 0	$ 1,963,000
Scenario Forecast
Income Taxes
Effective tax rate							0.00%
License Fee
Cost of Product Sales
Cost of product sales				$ 5,000,000
Sunosi
Cost of Product Sales
Number of Asian markets | Market					12
Revenue milestones	$ 165,000,000				$ 165,000,000
Development milestones	$ 1,000,000				$ 1,000,000
Auvelity
Cost of Product Sales
License agreement royalty as a percent of net sales					3.00%
Jazz Pharmaceuticals Plc | Sunosi
Cost of Product Sales
Number of Asian markets | Market	12